Skip to main content
TipRanks
Go Ultimate75% OFF

Eli Lilly & Co (LLY) AI Stock Analysis

23,961 Followers
LLY

Eli Lilly & Co

(NYSE:LLY)

Select Model
Rating:80Outperform
Price Target:$1,580.00â–²(10.36% Upside)
Action:reiterated
Date:10/30/26

The score is driven primarily by exceptional financial performance (very high margins and large cash generation) and a constructive technical uptrend. The latest earnings call reinforces momentum via raised guidance and strong product uptake, but valuation is a meaningful offset due to a high P/E and low dividend yield, and technical indicators show overbought conditions that add near-term volatility risk.

Positive Factors
Exceptional revenue growthRapid growth across leading metabolic medicines and multiple therapeutic areas indicates strong demand, expanding patient adoption, and increasing commercial scale. Broadening growth beyond a single product can support durable revenue momentum and strengthen Lilly’s position over the next several quarters.
Negative Factors
Persistent pricing pressureLower realized prices can constrain revenue quality and margin expansion even when prescription volumes grow. Continued payer and government pricing pressure may require Lilly to depend increasingly on sustained volume gains, product launches, and mix improvements to preserve earnings momentum.

Eli Lilly & Co Key Performance Indicators (KPIs)

Revenue by GeographyMaps revenue across countries and regions to show market concentration and diversification. A heavy tilt toward a single market increases vulnerability to local policy or pricing shifts, while broad geographic growth suggests more durable sales and opportunity to offset regional downturns.

$0.00$5.00B$10.00B$15.00B$20.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

International markets have shifted from support roles to primary growth drivers—Europe and Rest of World show clear step‑ups tied to rapid Mounjaro/Zepbound adoption and access wins, with China and Japan accelerating more recently. The U.S. remains the largest revenue base, but the global diversification materially reduces reliance on U.S. net‑price trends and helps explain the guidance raise; watch H2 seasonality, rebate/price dynamics and retatrutide regulatory timing as key risks that could temper this volume‑led momentum.

Data provided by:The Fly

Eli Lilly & Co (LLY) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%LLY+38.06%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.35T
Dividend Yield
0.48%
Average Volume (3M)
2.59M
Price to Earnings (P/E)
46.5
Beta (1Y)
0.44
Revenue Growth
45.51%
EPS Growth
50.48%
Country
US
Employees
50,000
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - General

Eli Lilly & Co Business Overview & Revenue Model

Company Description

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This e...

How the Company Makes Money

Eli Lilly primarily makes money by selling patented, branded prescription medicines. Revenue is recognized largely from product sales to wholesalers, distributors, pharmacies, hospitals, and other customers, with net sales reduced by estimated rebate...

Eli Lilly & Co Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:11.26%|Next Earnings Date:Feb 10, 2027
Earnings Call SentimentPositive

The call was strongly positive. Lilly reported 39% quarterly revenue growth, raised full-year guidance, delivered broad product and international growth, demonstrated strong uptake for Mounjaro, Zepbound, the Medicare Bridge program, and Foundayo, and advanced regulatory, clinical, manufacturing, and business-development initiatives. The main challenges were U.S. and expected future pricing pressure, nonrecurring 2026 revenue benefits, higher investment spending, oral-adherence uncertainty, adverse-event discontinuations at the highest Olora-TZP dose, and ongoing regulatory and reimbursement timing. Highlights significantly outweighed the lowlights.

Positive Updates

Strong Q3 Revenue Growth
Q3 revenue grew 39% compared with Q3 2025, or nearly $7 billion, driven by Mounjaro, Zepbound, and strong momentum across therapeutic areas. Key product revenue increased by over $6 billion.

Negative Updates

U.S. Price Declines
U.S. revenue increased 34%, but this was partially offset by a 7% decline in price. Excluding a favorable adjustment to rebate and discount estimates, U.S. price declined 10%.

Company Guidance

For 2026, Lilly expects full year revenue to be between $91 and $92 billion, non GAAP performance margin to be between 52.5%, and non GAAP earnings per share of $35 to $36, reflecting an increase of $4.07 per share at the midpoint of the range before updates to the Q3 acquired IPR&D charges of $4.57 per share. For 2027, Lilly expects sustained volume growth in the incretin market, the full year impact of the Medicare GLP-1 bridge access, and the launch of Foundayo in type 2 diabetes in The US; outside The US, it expects Mounjaro's leadership position to continue and expects to launch Foundayo, which will drive additional market growth. Lilly expects net realized price to be a headwind more than offset by volume growth, while noting that 2026 revenue benefited from approximately $2 billion of 1-time items primarily related to milestones payments and changes in estimates for rebates and discounts that it does not expect to recur; it expects a global rollout of Foundayo in all major markets in 2027.

Eli Lilly & Co Financial Statement Overview

Summary

Financial statements are very strong overall: exceptional profitability (TTM net margin ~32% and EBIT margin ~39%) and large absolute cash generation (TTM operating cash flow ~$30.6B; free cash flow ~$19.7B). Offsetting factors are a still debt-heavy balance sheet (TTM debt-to-equity ~1.23) and uneven cash-flow consistency/cash conversion versus earnings, including prior-year free-cash-flow volatility.

Income Statement

93Very Positive

Balance Sheet

76Positive

Cash Flow

81Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue86.46B65.18B45.04B34.12B28.54B28.32B
Gross Profit72.31B54.13B36.63B27.04B21.91B21.01B
EBITDA44.75B31.69B18.81B8.57B8.66B8.04B
Net Income27.58B20.64B10.59B5.24B6.24B5.58B
Balance Sheet
Total Assets148.07B112.48B78.71B64.01B49.49B48.81B
Cash, Cash Equivalents and Short-Term Investments4.88B7.27B3.42B2.93B2.21B3.91B
Total Debt49.50B42.50B33.64B25.23B16.24B16.88B
Total Liabilities107.80B85.94B64.44B53.14B38.71B39.65B
Stockholders Equity40.27B26.54B14.19B10.77B10.65B8.98B
Cash Flow
Free Cash Flow19.66B8.97B3.76B792.50M4.60B5.39B
Operating Cash Flow30.64B16.81B8.82B4.24B7.59B7.37B
Investing Cash Flow-30.41B-10.97B-9.30B-7.15B-3.76B-2.87B
Financing Cash Flow-5.14B-2.21B1.23B3.50B-5.41B-4.13B

Eli Lilly & Co Technical Analysis

Technical Analysis SentimentPositive
Last Price1431.67

Price Trends

50DMA1245.28Positive
100DMA1217.09Positive
200DMA1108.29Positive

Market Momentum

MACD55.99Negative
RSI67.03Neutral
STOCH76.38Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LLY, the sentiment is Positive. The current price of 1431.67 is above the 20-day moving average (MA) of 1364.33, above the 50-day MA of 1245.28, and above the 200-day MA of 1108.29, indicating a bullish trend. The MACD of 55.99 indicates Negative momentum. The RSI at 67.03 is Neutral, neither overbought nor oversold. The STOCH value of 76.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LLY.

Eli Lilly & Co Risk Analysis

Eli Lilly & Co disclosed 16 risk factors in its most recent earnings report. Eli Lilly & Co reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.Our use of artificial intelligence (AI) or other emerging technologies could adversely impact our business and financial results.Q4, 2023

Eli Lilly & Co Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

LLY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
LLYLLY80Outperform$1.35T46.5483.65%0.48%45.51%50.48%
NVONVO78Outperform$185.94B11.1854.14%4.32%11.16%15.62%
AMGNAMGN75Outperform$250.07B26.6585.59%2.15%8.60%33.48%
ABBVABBV71Outperform$520.65B50.56-202.43%2.35%10.68%338.08%
PFEPFE66Neutral$164.50B40.864.60%5.96%1.34%-58.96%
MRKMRK64Neutral$356.13B147.395.29%2.35%5.21%-86.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%60%LLYAMGNMRKNVOPFEABBVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
LLY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
LLYEli Lilly And Company1431.67388.3837.23%
AMGNAmgen Inc462.32129.1638.77%
MRKMerck & Company144.4652.1256.45%
NVONovo Nordisk41.60-5.79-12.21%
PFEPfizer Inc28.865.5423.77%
ABBVAbbvie294.5568.4130.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026